Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.
Bitterroot Bio has raised $145.0M in total funding. The most recent round was Series A. The last funding was announced in June 2023.
Bitterroot Bio's investors include ARCH Venture Partners, Deerfield, Google Ventures, Alexandria Venture Investments, Koch Disruptive Technologies.
Bitterroot Bio is headquartered in Palo Alto, United States.
Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.
Bitterroot Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Bitterroot Bio — Funding & Investors." VCBacked, June 7, 2023, https://www.vcbacked.co/company/bitterroot-bio. Accessed July 19, 2026.
VCBacked. (2023). Bitterroot Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/bitterroot-bio
{{cite web |title=Bitterroot Bio — Funding & Investors |url=https://www.vcbacked.co/company/bitterroot-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated